Literature DB >> 12411508

Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability.

Niels Mailand1, Alexandre V Podtelejnikov, Anja Groth, Matthias Mann, Jiri Bartek, Jiri Lukas.   

Abstract

DNA replication in higher eukaryotes requires activation of a Cdk2 kinase by Cdc25A, a labile phosphatase subject to further destabilization upon genotoxic stress. We describe a distinct, markedly stable form of Cdc25A, which plays a previously unrecognized role in mitosis. Mitotic stabilization of Cdc25A reflects its phosphorylation on Ser17 and Ser115 by cyclin B-Cdk1, modifications required to uncouple Cdc25A from its ubiquitin-proteasome-mediated turnover. Cdc25A binds and activates cyclin B-Cdk1, accelerates cell division when overexpressed, and its downregulation by RNA interference (RNAi) delays mitotic entry. DNA damage-induced G(2) arrest, in contrast, is accompanied by proteasome-dependent destruction of Cdc25A, and ectopic Cdc25A abrogates the G(2) checkpoint. Thus, phosphorylation-mediated switches among three differentially stable forms ensure distinct thresholds, and thereby distinct roles for Cdc25A in multiple cell cycle transitions and checkpoints.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411508      PMCID: PMC131064          DOI: 10.1093/emboj/cdf567

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  60 in total

1.  CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.

Authors:  E Vigo; H Müller; E Prosperini; G Hateboer; P Cartwright; M C Moroni; K Helin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.

Authors:  C Y Peng; P R Graves; R S Thoma; Z Wu; A S Shaw; H Piwnica-Worms
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

3.  Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases.

Authors:  I Blomberg; I Hoffmann
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

5.  Understanding the cell cycle.

Authors:  P Nurse; Y Masui; L Hartwell
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

6.  DNA signals for G2 checkpoint response in diploid human fibroblasts.

Authors:  W K Kaufmann; P E Kies
Journal:  Mutat Res       Date:  1998-05-25       Impact factor: 2.433

7.  14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts.

Authors:  A Kumagai; P S Yakowec; W G Dunphy
Journal:  Mol Biol Cell       Date:  1998-02       Impact factor: 4.138

8.  Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity.

Authors:  R N Booher; P S Holman; A Fattaey
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

9.  Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.

Authors:  W Wu; Y H Fan; B L Kemp; G Walsh; L Mao
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

10.  The cdc25B phosphatase is essential for the G2/M phase transition in human cells.

Authors:  C Lammer; S Wagerer; R Saffrich; D Mertens; W Ansorge; I Hoffmann
Journal:  J Cell Sci       Date:  1998-08       Impact factor: 5.285

View more
  96 in total

1.  Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism.

Authors:  Katsuhiro Uto; Daigo Inoue; Ken Shimuta; Nobushige Nakajo; Noriyuki Sagata
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

2.  How adeno-associated virus Rep78 protein arrests cells completely in S phase.

Authors:  Carole Berthet; Kenneth Raj; Philippe Saudan; Peter Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

Review 3.  Ubiquitin and SUMO systems in the regulation of mitotic checkpoints.

Authors:  Gustavo J Gutierrez; Ze'ev Ronai
Journal:  Trends Biochem Sci       Date:  2006-05-02       Impact factor: 13.807

Review 4.  Interlinking interleukin-7.

Authors:  Christina Kittipatarin; Annette R Khaled
Journal:  Cytokine       Date:  2007-09-04       Impact factor: 3.861

5.  Consequences of the selective blockage of chaperone-mediated autophagy.

Authors:  Ashish C Massey; Susmita Kaushik; Guy Sovak; Roberta Kiffin; Ana Maria Cuervo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase.

Authors:  Jianping Jin; Takahiro Shirogane; Lai Xu; Grzegorz Nalepa; Jun Qin; Stephen J Elledge; J Wade Harper
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase.

Authors:  Jeremy P H Chow; Wai Yi Siu; Tsz Kan Fung; Wan Mui Chan; Anita Lau; Talha Arooz; Chuen-Pei Ng; Katsumi Yamashita; Randy Y C Poon
Journal:  Mol Biol Cell       Date:  2003-07-25       Impact factor: 4.138

Review 8.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

9.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Authors:  Nicholas C Turner; Christopher J Lord; Elizabeth Iorns; Rachel Brough; Sally Swift; Richard Elliott; Sydonia Rayter; Andrew N Tutt; Alan Ashworth
Journal:  EMBO J       Date:  2008-04-03       Impact factor: 11.598

10.  PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Authors:  Ankita Jhuraney; Nicholas T Woods; Gabriela Wright; Lily Rix; Fumi Kinose; Jodi L Kroeger; Elizabeth Remily-Wood; W Douglas Cress; John M Koomen; Stephen G Brantley; Jhanelle E Gray; Eric B Haura; Uwe Rix; Alvaro N Monteiro
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.